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Acute myeloid leukemia (AML) cells home to the endosteal region of the bone marrow. They interact with bone marrow stromal
components including extracellular matrix proteins, glycosaminoglycans, and stromal cells, by which they derive proliferative and
growth inhibitory signals. Furthermore, adhesion to marrow stroma confers chemotherapy drug resistance and thereby promotes
leukemia survival. A subpopulation of the leukemic blasts, known as leukemia stem cells, that are capable of propagating the
leukemia, remain sheltered in the bone marrow microenvironment, exhibit resistance to chemotherapy, and serve as the origin of
relapse after a variable period of remission. Detachment of these cells from the bone marrow in combination with chemotherapy
may improve the outcome of therapy for AML.
1. Adhesion and Leukemia Biology
Adhesive properties of leukemia cells are likely responsible
for the complication of leukostasis in AML as well as leuke-
mic meningitis, leukemia cutis, extramedullary leukemia,
and formation of chloromas. Three receptors, VLA- (very
late antigen-) 4, CXCR4, and CD44, play a critical role in
normal stem cell homing and also appear to be paramount
to the homing of AML cells to, or retention within, the bone
marrow. VLA4 is the α4β1 integrin that mediates adhesion
to alternatively spliced ﬁbronectin and cellular vascular cell
adhesion molecule-1 (VCAM1). CXCR4 is a chemokine
receptor for stromal derived factor-1 (SDF-1) also known
as CXCL12. CD44 is a hyaluronic acid receptor that is an
E selectin ligand expressed by hematopoietic stem cells
known as HCELL when properly glycosylated [1]. The VLA-
4/VCAM-1 pathway has been implicated in the attachment
of leukemic blasts to the vessel wall [2]. Both CXCR-4 and
VLA-4 mediate migration of AML blasts [3, 4] .T h er o l eo f
CXCR4 in leukemia retention was illustrated by experiments
that demonstrated reduction of primary human AML cell
numbers previously engrafted in immunodeﬁcient NODscid
mice with antibody to CXCR-4 [5]. In contrast, there was
no decrease in normal human CD34+ cell numbers in mice
engrafted with normal human cord blood mononuclear
cells after treatment with the anti-CXCR4 antibody [5]. This
ﬁnding highlights the exquisite ongoing dependence of the
engraftment of human AML in immunodeﬁcient mice on
CXCR-4. In addition, the CD44 hyaluronic acid receptor
is involved in homing of normal human CD34+ cells [6].
Similarly, administration of an antibody to CD44 blocked
engraftment of AML cells in NOD-scid mice [7]. Further-
more, high level expression of CD44 by leukemia cells was
suﬃcient to generate leukemia by leukemia-initiating cells
even after withdrawal of overexpression of the HoxA10 gene
that initiated the leukemia [8]. Thus, at least three adhesion
mechanisms, CXCR4/SDF1 (CXCL12), VLA-4/VCAM-1 or
ﬁbronectin, and CD44/ligand, function in acute myeloid
leukemia migration, retention, and survival (Figure 1).
Not only are leukemia cells dependent on the bone mar-
row stroma for survival, but also they are capable of dis-
torting normal bone marrow niches in a manner that aﬀects
normal hematopoietic progenitor cells [9]. The endo-steal
region was the location identiﬁed as the site of homing of
chemotherapy-resistant AML stem cells [10], supporting the
concept of localizing niches for certain cell types, and this
location is the same region as a niche for normal homing
hematopoietic stem cells [11].2 The Scientiﬁc World Journal
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Figure 1: Leukemia cell adhesion and chemokine receptors in stro-
mal interactions. CXCR4, VLA-4, and CD44 play critical roles in
leukemia cell homing and migration.
2. Adhesion and Chemotherapy Resistance
Adhesion of acute myeloid leukemia cells confers resistance
to several chemotherapy agents, including cytarabine, one
of the most active agents in AML. This ability is known as
environment-mediated drug resistance (EMDR) [12]. The
theory is that this capacity, particularly when possessed
by leukemia stem cells, for example, gives rise to minimal
residual disease, which in turn, is the origin of relapse
after a period of genetic instability and acquisition of more
complex drug resistance. Growth of AML cells on HS-5
stroma reduced daunorubicin- or cytarabine-induced apop-
tosis [13]. Adhesion of U937 to ﬁbronectin via β1 integrins
inhibits mitoxantrone- and etoposide-induced apoptosis
[14]; similarly, adhesion of U937 or HL60 leukemia cell lines
to ﬁbronectin inhibited daunorubicin or cytarabine induced
apoptosis [15]. Adhesion of primary patient AML cells to
ﬁbronectin or immobilized VCAM-1 conferred resistance to
cytarabine or daunorubcin plus cytarabine [16]. Agents that
block adhesion mediated by VLA-4, including a ﬁbronectin
peptide [17], antibody to VLA-4 [15, 16], soluble VCAM-
1[ 16], a small molecule inhibitor of VLA-4 [18], or a
peptide inhibitor of CXCR-4 [19] all overcame adhesion
mediated chemotherapy resistance. Moreover, a peptide
inhibitor of the chemokine receptor, CXCR4, exhibited
direct cytotoxicity against AML and multiple myeloma cells
in vitro and in xenografts [20]. The CXCR4 inhibitor
AMD3100 worked synergistically with histone deacetylase
inhibitor panobinostat to induce apoptosis of AML cells in
vitro [21]. Another CXCR4 inhibitor, AMD3465, interfered
with chemotaxis of AML cells toward SDF1 in vitro,
prevented SDF1-induced activation of survival pathways in
AML cells, caused mobilization of human leukemia cells
in immunodeﬁcient mouse xenografts, and enhanced the
activity of sorafenib in Flt3-positive AML [22]. In an in vivo
murine model of acute promyelocytic leukemia, AMD3100
mobilized leukemia cells into the blood and, in combination
with cytarabine, reduced leukemic burden and prolonged
animal survival [23]. These latter two studies demonstrated
the proof of principle that the concept that a combination of
a CXCR4 inhibitor with chemotherapy or targeted therapy
was eﬃcacious in enhancing leukemia cytotoxicity in vivo.
Several potential mechanisms have been proposed for
the ability of integrin-mediated signaling to protect from
chemotherapy toxicity that involve activation of survival
pathways or inhibition of apoptosis. The speciﬁc pathways
include activation of the PI3K/Akt/bcl-2 pathway [15], an
interaction between Wnt and adhesion-dependent signaling
pathways [24], and increased degradation of proapoptotic
bcl-2 family member Bim [25]. Integrin-linked kinase (ILK)
also plays a role in the activation of Akt upon adhesion of
AML cells [26, 27].
3. Chemokine Receptor or Adhesion Receptor
Expressionand Prognosis
Expression of each of the two receptors, VLA-4 or CXCR4,
has been associated with prognosis in AML; the former is
correlated with better survival, and the latter portends worse
survival. Several studies showed that high-level expression
of CXCR4 was associated with poor prognosis in AML. As
describedearlier,CXCR-4wasdemonstratedtohaveapivotal
role in the homing, migration, and development of human
AML in the NODscid murine mutant [5]. Although not
all AML patient cells tested exhibited surface expression of
CXCR-4withaverageexpression24%,allAMLcellsanalyzed
uniformlyexhibitedinternalexpressionofCXCR-4afterper-
meabilization and labeling [5]. AML patients with high-level
(≥20%) expression of CXCR-4 by the CD34+ population
exhibited reduced overall survival and relapse free survival
[28]. By multivariate Cox regression analysis, high CXCR-4
expression had a relative risk for relapse of 13.4 (P<0.001)
[28]. Furthermore, an independent study also corroborated
that high-level CXCR-4 expression predicted overall and
event-free survival in patients with normal karyotype and
unmutated Flt3 status [29], and lower expression of CXCR4
correlated with longer relapse-free and overall survival
[30] or higher complete remission rate [31]. Presence of
functional circulating CXCR4 bearing microparticles was
correlated with high white blood count in AML patients and
wasproposed tobeinvolved inAMLprogression,possibly by
promoting dissemination of leukemia [32].
In contrast to CXCR4 expression, high-level VLA-4 ex-
pressionhastheoppositeeﬀectonprognosisinAML.Higher
functional expression of VLA-4 was shown to correlate
with longer survival for newly diagnosed adult AML [16].
Furthermore, higher expression of VLA-4 by ﬂow cytometry
correlated with better prognosis of pediatric AML patients
[33]. These two large studies are in contrast with an
earlier, smaller trial that suggested that VLA-4 expression
conferred poor prognosis [15]. The precise mechanism for
this improved survival is unknown, but one hypothesis is
that as soluble VCAM-1 (sVCAM-1) levels are elevated in
AML [34], the AML blasts may be dislodged from the bone
marrow due to binding of sVCAM-1 and thus be more
susceptible to chemotherapy.
4. ClinicalTrialsof Adhesion InhibitorsinAML
There are several ongoing clinical trials utilizing this novel
concept of combining agents that mobilize leukemia with
chemotherapy (Table 1). For example, there is an ongoing
multicenter phase I trial of plerixafor in combination withThe Scientiﬁc World Journal 3
Table 1: Clinical trials of combinations of adhesion inhibitors and chemotherapy for AML.
Title Clinicaltrials.gov designation Institution or sponsor
Study of plerixafor combined with
cytarabine and daunorubicin in patients
with newly diagnosed acute myeloid
leukemia
NCT00990054 Multicenter-Genzyme-Sanoﬁ
First in human study to determine the
safety, tolerability, and preliminary
eﬀectiveness of MDX-1338 (BMS936564)
in subjects with acute myelogenous
leukemia (AML)
NCT01120457 Multicenter-Bristol-Myers Squibb
Granulocyte colony-stimulating factor
(G-CSF) and plerixafor plus sorafenib for
acute myelogenous leukemia (AML) with
FLT3 mutations
NCT00943943 MD Anderson Cancer Center
Chemosensitization with plerixafor plus
G-CSF in acute myeloid leukemia NCT00906945 Washington University
IV plerixafor with mitoxantrone
etoposide and cytarabine for acute
myeloid leukemia (AML)
NCT01027923 Washington University
Plerixafor and clofarabine in frontline
treatment of elderly patients with acute
myelogenous leukemia (AML)
NCT01160354 MD Anderson Cancer Center
standard induction “7 + 3” chemotherapy in AML including
high-dose daunorubicin 90mg/m2 daily for three days.
There is also an ongoing multicenter phase I trial of an
anti-CXCR-4 antibody in combination with mitoxantrone,
etoposide, and cytarabine for relapsed/refractory AML. As
these inhibitors enter the clinic, we will ascertain their ability
tomobilizeAMLoutoftheprotectedmarrowmicroenviron-
ment and determine if this approach improves outcome of
patients with new diagnosis or relapsed/refractory AML.
5.FutureProspects
In summary, there may be several critical mechanisms for
adhesion of AML within the bone marrow, and discovery of
novel mechanisms and novel inhibitors targeting disruption
of adhesion may provide a signiﬁcant advance in the
treatment of AML.
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